159 related articles for article (PubMed ID: 3366182)
21. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
[TBL] [Abstract][Full Text] [Related]
22. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Wang SX
Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
[TBL] [Abstract][Full Text] [Related]
23. [Cholecystokinin and its antagonists: effects on digestive motility].
Bruley des Varannes S; Cloarec D; Dubois A; Galmiche JP
Gastroenterol Clin Biol; 1991; 15(10):744-57. PubMed ID: 1816015
[No Abstract] [Full Text] [Related]
24. Effect of bethanechol and metoclopramide on upper gastrointestinal motility in the kitten.
Hillemeier C; McCallum R; Oertel R; Gryboski J
J Pediatr Gastroenterol Nutr; 1986 Jan; 5(1):134-7. PubMed ID: 2868086
[TBL] [Abstract][Full Text] [Related]
25. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
26. Effects of peripheral CCK receptor blockade on gastric emptying in rats.
Reidelberger RD; Kelsey L; Heimann D; Hulce M
Am J Physiol Regul Integr Comp Physiol; 2003 Jan; 284(1):R66-75. PubMed ID: 12388446
[TBL] [Abstract][Full Text] [Related]
27. The role of cholecystokinin in interleukin-1-induced anorexia.
Daun JM; McCarthy DO
Physiol Behav; 1993 Aug; 54(2):237-41. PubMed ID: 8372116
[TBL] [Abstract][Full Text] [Related]
28. General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride.
Megens AA; Awouters FH; Niemegeers CJ
Arzneimittelforschung; 1991 Jun; 41(6):631-4. PubMed ID: 1930352
[TBL] [Abstract][Full Text] [Related]
29. CGRP 8-37[correction of 8-27] blocks the inhibition of gastric emptying induced by intravenous injection of alpha-CGRP in rats.
Plourde V; St-Pierre S; Fournier A; Taché Y
Life Sci; 1993; 52(10):857-62. PubMed ID: 8383261
[TBL] [Abstract][Full Text] [Related]
30. Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718, a specific inhibitor of CCK-receptor binding.
Rossetti L; Shulman GI; Zawalich WS
Diabetes; 1987 Oct; 36(10):1212-5. PubMed ID: 3308589
[TBL] [Abstract][Full Text] [Related]
31. Gastric loads potentiate inhibition of food intake produced by a cholecystokinin analogue.
Schwartz GJ; Netterville LA; McHugh PR; Moran TH
Am J Physiol; 1991 Nov; 261(5 Pt 2):R1141-6. PubMed ID: 1951762
[TBL] [Abstract][Full Text] [Related]
32. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
Millington WR; Mueller GP; Lavigne GJ
J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
[TBL] [Abstract][Full Text] [Related]
33. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients.
McCallum RW; Fink SM; Lerner E; Berkowitz DM
Gastroenterology; 1983 Jun; 84(6):1573-7. PubMed ID: 6132852
[TBL] [Abstract][Full Text] [Related]
34. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.
Cantor P; Mortensen PE; Myhre J; Gjorup I; Worning H; Stahl E; Survill TT
Gastroenterology; 1992 May; 102(5):1742-51. PubMed ID: 1568584
[TBL] [Abstract][Full Text] [Related]
35. Effect of metoclopramide, bethanechol, and loperamide on gastric residence time, gastric emptying, and mouth-to-cecum transit time.
Kirby MG; Dukes GE; Heizer WD; Bryson JC; Powell JR
Pharmacotherapy; 1989; 9(4):226-31. PubMed ID: 2771808
[TBL] [Abstract][Full Text] [Related]
36. Endogenous cholecystokinin reduces feeding in young rats.
Weller A; Smith GP; Gibbs J
Science; 1990 Mar; 247(4950):1589-91. PubMed ID: 2321020
[TBL] [Abstract][Full Text] [Related]
37. Effects of MK-329 on gastric emptying of solids in cats.
Hornof WJ; Koblik PD
J Nucl Med; 1991 Mar; 32(3):547-8. PubMed ID: 2005467
[No Abstract] [Full Text] [Related]
38. The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat.
Hayward NJ; Harding M; Lloyd SA; McKnight AT; Hughes J; Woodruff GN
Br J Pharmacol; 1991 Dec; 104(4):973-7. PubMed ID: 1687371
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
40. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists.
Lotti VJ; Cerino DJ; Kling PJ; Change RS
Life Sci; 1986 Nov; 39(18):1631-8. PubMed ID: 3773639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
